• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT VASCULAR ABSORB BIORESORBABLE VASCULAR SCAFFOLD SYSTEM; BIORESORBABLE SCAFFOLD

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT VASCULAR ABSORB BIORESORBABLE VASCULAR SCAFFOLD SYSTEM; BIORESORBABLE SCAFFOLD Back to Search Results
Catalog Number UNK ABSORB
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Myocardial Infarction (1969); Thrombosis (2100)
Event Date 01/01/2016
Event Type  Injury  
Manufacturer Narrative
Dates estimated the patient deaths referenced in event description will be filed under a separate medwatch report #.The device was not returned for analysis.A review of the lot history record and complaint history of the reported lot could not be conducted because the lot and part number were not provided.A conclusive cause for the difficulties listed and the reported patient effects can not be determined based on the limited information available.The patient effects listed are consistent with the product risk profile and are therefore expected.There is no indication of a product quality issue with respect to manufacture, design or labeling.The udi is unknown as the part and lot numbers were not provided.The xience and xience prime referenced in event description are being filed under separate medwatch report #s.Article title: poly (l-lactic acid) bioresorbable scaffolds versus metallic drug-eluting stents for the treatment of coronary artery disease: a meta-analysis of 11 randomized trials.
 
Event Description
It was reported through a research article identifying absorb, xience prime, and xience that may be related to the following: patient death, myocardial infarction, thrombosis, revascularization, and rehospitalization.This article summarizes clinical outcomes of 10,707 patients that were treated with xience/xience prime stents and absorb scaffolds.Specific patient information is documented as unknown.Details are listed in the article, titled "poly (l-lactic acid) bioresorbable scaffolds versus metallic drug-eluting stents for the treatment of coronary artery disease: a meta-analysis of 11 randomized trials.".
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ABSORB BIORESORBABLE VASCULAR SCAFFOLD SYSTEM
Type of Device
BIORESORBABLE SCAFFOLD
Manufacturer (Section D)
ABBOTT VASCULAR
26531 ynez rd.
temecula CA 92591 4628
Manufacturer (Section G)
ABBOTT VASCULAR, REG # 2024168
26531 ynez road
temecula CA 92591 4628
Manufacturer Contact
lindsey bell
26531 ynez rd.
temecula, CA 92591-4628
9519143996
MDR Report Key10801855
MDR Text Key215069586
Report Number2024168-2020-09298
Device Sequence Number1
Product Code PNY
Combination Product (y/n)Y
Reporter Country CodeIT
PMA/PMN Number
P150023
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type literature
Reporter Occupation Physician
Type of Report Initial
Report Date 11/06/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/06/2020
Is this an Adverse Event Report? Yes
Device Operator Health Professional
Device Catalogue NumberUNK ABSORB
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received10/21/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention; Disability;
-
-